25-Oct-2024
No headlines found.
Globe Newswire (Mon, 16-Sep 7:30 AM ET)
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Globe Newswire (Wed, 4-Sep 8:00 AM ET)
Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
Globe Newswire (Tue, 13-Aug 4:05 PM ET)
Checkpoint Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Updates
Globe Newswire (Mon, 12-Aug 8:30 AM ET)
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
Checkpoint Therapeutics trades on the NASDAQ stock market under the symbol CKPT.
As of October 25, 2024, CKPT stock price climbed to $3.67 with 1,411,070 million shares trading.
CKPT has a beta of 0.89, meaning it tends to be less sensitive to market movements. CKPT has a correlation of 0.01 to the broad based SPY ETF.
CKPT has a market cap of $165.22 million. This is considered a Micro Cap stock.
Last quarter Checkpoint Therapeutics reported $41,000 in Revenue and -$.18 earnings per share. This beat revenue expectation by $21,000 and exceeded earnings estimates by $.12.
In the last 3 years, CKPT traded as high as $46.40 and as low as $1.30.
The top ETF exchange traded funds that CKPT belongs to (by Net Assets): VTI, VXF, IWC.
CKPT has outperformed the market in the last year with a price return of +78.2% while the SPY ETF gained +40.4%. CKPT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +38.0% and +50.7%, respectively, while the SPY returned +7.9% and -0.1%, respectively.
CKPT support price is $3.28 and resistance is $3.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CKPT shares will trade within this expected range on the day.